These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23587028)

  • 1. Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs).
    Westerberg PA; Tivesten Å; Karlsson MK; Mellström D; Orwoll E; Ohlsson C; Larsson TE; Linde T; Ljunggren Ö
    BMC Nephrol; 2013 Apr; 14():85. PubMed ID: 23587028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients.
    Sugimoto H; Ogawa T; Iwabuchi Y; Otsuka K; Nitta K
    Int Urol Nephrol; 2014 Jan; 46(1):99-106. PubMed ID: 23355029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.
    Nakano C; Hamano T; Fujii N; Obi Y; Matsui I; Tomida K; Mikami S; Inoue K; Shimomura A; Nagasawa Y; Okada N; Tsubakihara Y; Rakugi H; Isaka Y
    Bone; 2012 Jun; 50(6):1266-74. PubMed ID: 22425694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
    De Jong MA; Eisenga MF; van Ballegooijen AJ; Beulens JWJ; Vervloet MG; Navis G; Gansevoort RT; Bakker SJL; De Borst MH
    Nephrol Dial Transplant; 2021 Jan; 36(1):121-128. PubMed ID: 32124925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.
    Brandenburg VM; Kleber ME; Vervloet MG; Tomaschitz A; Pilz S; Stojakovic T; Delgado G; Grammer TB; Marx N; März W; Scharnagl H
    Atherosclerosis; 2014 Nov; 237(1):53-9. PubMed ID: 25200615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes.
    Dominguez JR; Shlipak MG; Whooley MA; Ix JH
    J Am Soc Nephrol; 2013 Mar; 24(4):647-54. PubMed ID: 23520205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men.
    Marsell R; Grundberg E; Krajisnik T; Mallmin H; Karlsson M; Mellström D; Orwoll E; Ohlsson C; Jonsson KB; Ljunggren O; Larsson TE
    Eur J Endocrinol; 2008 Jan; 158(1):125-9. PubMed ID: 18166826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E; Yoshida M; Sasaki S
    BMC Nephrol; 2012 Sep; 13():122. PubMed ID: 23013306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.
    Ginsberg C; Craven TE; Chonchol MB; Cheung AK; Sarnak MJ; Ambrosius WT; Killeen AA; Raphael KL; Bhatt UY; Chen J; Chertow GM; Freedman BI; Oparil S; Papademetriou V; Wall BM; Wright CB; Ix JH; Shlipak MG;
    Clin J Am Soc Nephrol; 2018 Dec; 13(12):1816-1824. PubMed ID: 30425104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
    Munoz Mendoza J; Isakova T; Cai X; Bayes LY; Faul C; Scialla JJ; Lash JP; Chen J; He J; Navaneethan S; Negrea L; Rosas SE; Kretzler M; Nessel L; Xie D; Anderson AH; Raj DS; Wolf M;
    Kidney Int; 2017 Mar; 91(3):711-719. PubMed ID: 28017325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast Growth Factor 23 Predicts All-Cause Mortality in a Dose-Response Fashion in Pre-Dialysis Patients with Chronic Kidney Disease.
    Xue C; Yang B; Zhou C; Dai B; Liu Y; Mao Z; Yu S; Mei C
    Am J Nephrol; 2017; 45(2):149-159. PubMed ID: 28006765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.
    Eisenga MF; De Jong MA; Van der Meer P; Leaf DE; Huls G; Nolte IM; Gaillard CAJM; Bakker SJL; De Borst MH
    PLoS Med; 2019 Jun; 16(6):e1002818. PubMed ID: 31170159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
    J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.
    Nakano C; Hamano T; Fujii N; Matsui I; Tomida K; Mikami S; Inoue K; Obi Y; Okada N; Tsubakihara Y; Isaka Y; Rakugi H
    Clin J Am Soc Nephrol; 2012 May; 7(5):810-9. PubMed ID: 22362065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study.
    Haring R; Enserro D; Xanthakis V; Mitchell GF; Benjamin EJ; Hamburg NM; Sullivan L; Nauck M; Wallaschofski H; Vasan RS
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27385427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation.
    Baia LC; Humalda JK; Vervloet MG; Navis G; Bakker SJ; de Borst MH;
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1968-78. PubMed ID: 23929933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloperoxidase and the Risk of CKD Progression, Cardiovascular Disease, and Death in the Chronic Renal Insufficiency Cohort (CRIC) Study.
    Correa S; Pena-Esparragoza JK; Scovner KM; Waikar SS; Mc Causland FR
    Am J Kidney Dis; 2020 Jul; 76(1):32-41. PubMed ID: 31864821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.